KRAS and cancer: GO analysis of those 712 differentially expressed genes induced by KRAS G12V revealed that the downstream target genes of the KRAS mutant are enriched in pathways involved in RAS and MAPK signaling pathways and platinum resistance, as well as pathways in cancer (Figure 4B).